AOL Money & Finance

map pharma posts

Feed

Analyst upgrades, downgrades and initiations: HOT, GOOG, WPI, LYG ...

Analyst upgrades:
  • Baird upgraded Starwood Hotels (NYSE: HOT), Host Hotels (NYSE: HST) and Marriott (NYSE: MAR) to Outperform from Neutral based on valuation and indications that negative sentiment has reached a bottom.
  • Citigroup upgraded Torchmark (NYSE: TMK) to Buy from Hold as they find the valuation attractive and think management can grow earnings and book value in 2009/2010. Despite upgrading, the firm lowered their target price to $37 from $45.
  • ASM International (NASDAQ: ASMI) was added to Goldman's Conviction Buy List.
  • Credit Suisse (NYSE: CS) was raised to Overweight from Equal Weight at Morgan Stanley.
  • Live Nation (NYSE: LYV) was upgraded at Natixis to Buy from Hold.

Continue reading Analyst upgrades, downgrades and initiations: HOT, GOOG, WPI, LYG ...

Analyst initiations: ATML, SWKS, ALU, PRXL and MAPP

MOST NOTEWORTHY: Atmel, Skyworks, Alcatel-Lucent, Parexel and Map Pharma were today's noteworthy initiations:
  • Kaufman Bros. initiated Atmel (NASDAQ: ATML) with a Buy rating and $6 target, as they believe the company's increasing focus around its core microcontroller business can drive an improved growth and profitability profile going forward and would be buyers at current levels.
  • The firm also started shares of Skyworks (NASDAQ: SWKS) with a Buy rating and a $10 target, as they like the company's balanced customer positioning and find the stock attractively valued at current levels.
  • JP Morgan initiated Alcatel-Lucent (NYSE: ALU) with an Overweight rating and believes the risks are more than fully priced into shares at current levels.
  • Parexel (NADSAQ: PRXL) was initiated with a Neutral rating at Broadpoint, as they believe the company's improved execution is already priced into shares.
  • Deutsche Bank finds shares of Map Pharmaceuticals (NASDAQ: MAPP) attractively valued given the opportunity from the company's two late stage product candidates, UDB and Tempo Migraine. The firm started shares off with a Buy rating and $19 target.
OTHER INITIATIONS:

IPO & secondary preview -- Week of Oct. 1, 2007

Wall Street's equity market offers a full schedule this week, with 8 IPOs and 5 Secondaries on the docket.

Those deals tentatively scheduled to price include:

IPOs:

Possible

  • Merrion Pharmaceuticals (MERR), a 4M-share IPO for this pharmaceuticals company. Punk Zeigel is the lead manager. Filing range: $10.00-$12.00.

Early Week

  • Liberty Acquisition (LIA), an 86.25M-share IPO for this reorganization services company. Citigoup is the lead manager.

Continue reading IPO & secondary preview -- Week of Oct. 1, 2007

Symbol Lookup
IndexesChangePrice
DJIA+20.0310,246.97
NASDAQ-2.982,151.08
S&P 500-0.071,093.01

Last updated: November 10, 2009: 07:52 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance